Neon joins the biotech IPO fiesta on Nasdaq, bagging $100M in the latest display of enthusiasm for drug developers
Neon Therapeutics just barely made it into the big H1 group of biotech IPOs that’s landed so far this year.
Hopes of helping open a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
